GLP-1 receptor agonists in patients with cancer are associated with reduced all-cause mortality
GLP-1 Receptor Agonists in Cancer: Reduced Mortality Shown
Oncology & Diabetes
Cancer Survival
Glycemic Control
Type 2 Diabetes
What You Will Learn
- How GLP-1RAs compare to metformin for all-cause mortality in patients with type 2 diabetes and active cancer
- Which hospitalization-related outcomes — including sepsis, pneumonia, pulmonary embolism, and MACE — differ between treatment groups
- What happens to survival when patients already on metformin add a GLP-1RA versus insulin as a second agent
- Where the data are genuinely encouraging and where critical methodological gaps demand caution
TL;DR: In a propensity-matched retrospective cohort of patients with type 2 diabetes and active cancer, GLP-1 receptor agonist monotherapy was associated with a statistically significant 12.5% reduction in all-cause mortality compared to metformin monotherapy (HR 0.875; 95% CI 0.778–0.985), with additional reductions in hospitalization, sepsis, pneumonia, pulmonary embolism, and major adverse cardiovascular events.
Abstract
Context: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been reported to decrease cancer incidence, but less is known about their potential in patients with active cancer. Preclinical studies have demonstrated that GLP-1RAs inhibit progression of solid tumor malignancies via downregulation of cellular proliferation pathways and improved glycemic control. Despite these promising findings, studies characterizing the effects of GLP-1RAs in patients with active cancer are limited.
Objective: To evaluate the effects of GLP-1RAs on mortality and hospitalization in patients with type 2 diabetes and active cancer compared to those receiving metformin.
Methods: Using TriNetX, a global database comprising more than 120 million patients, the investigators identified an overall cohort of 3,747 patients with type 2 diabetes who received GLP-1RAs within 3 months of starting systemic therapy and identified 52,061 patients receiving metformin in the same timeframe as a control cohort. Additional subanalyses stratified patients by glycated hemoglobin A1c (HbA1c) range, obesity, and by participants newly started on their first instance of a GLP-1RA within 3 months of starting cancer treatment.
Results: Patients receiving GLP-1RAs had significantly reduced mortality both in the overall monotherapy setting (HR 0.875; 95% CI 0.778–0.985; P = .0268) and the new-start setting (HR 0.786; 95% CI 0.662–0.934; P = .0062). Secondary analyses found lower rates of all-cause hospitalization, sepsis, major adverse cardiovascular events, pulmonary embolism, and pneumonia in patients on GLP-1RAs. Subanalyses stratified by body mass index and HbA1c did not meet statistical significance.
Conclusion: Patients with diabetes and cancer who received GLP-1RAs experienced superior survival outcomes and reduced rates of hospitalization compared to patients receiving metformin. Patients already on metformin and newly started on GLP-1RAs demonstrated superior survival outcomes compared to patients newly started on insulin. Further prospective, well-controlled studies are needed to evaluate the benefits of GLP-1RAs in patients with diabetes and cancer.
Source: Mahadevan A, Vosooghi A, Arora JS, et al. GLP-1 receptor agonists in patients with cancer are associated with reduced all-cause mortality and hospitalization. J Clin Endocrinol Metab. 2026;111(6):1604–1612.
DOI: https://doi.org/10.1210/clinem/dgaf703
Advance Access: January 2, 2026 | Open Access (CC BY 4.0)
Study at a Glance
| Design | Retrospective propensity-matched cohort study using TriNetX (global EHR database, >120 million patients) |
| Population | Adults with type 2 diabetes and active cancer (solid and hematologic malignancies) receiving systemic therapy; January 2010 onward |
| Intervention | GLP-1RA monotherapy (liraglutide, dulaglutide, semaglutide, exenatide, tirzepatide) within 3 months of starting systemic cancer therapy |
| Comparator | Metformin monotherapy within the same timeframe; insulin as second comparator in the new-start cohort |
| Overall Cohort (post-match) | n = 3,551 per group (total 7,102) |
| New-Start Cohort (post-match) | n = 1,620 per group (GLP-1RA vs. insulin) |
| Primary Endpoint | All-cause mortality (Kaplan-Meier survival; index event: first day of systemic anticancer therapy; landmarked at 6 months) |
| Key Finding | GLP-1RA monotherapy associated with reduced all-cause mortality vs. metformin (HR 0.875; 95% CI 0.778–0.985; P = .0268); new-start GLP-1RA vs. insulin showed stronger separation (HR 0.786; 95% CI 0.662–0.934; P = .0062) |
Study Snapshot
| Outcome | Statistic | 95% CI | P-value |
|---|---|---|---|
| All-cause mortality (overall cohort) | HR 0.875 | 0.778–0.985 | .0268 |
| All-cause mortality (new-start GLP-1RA vs. insulin) | HR 0.786 | 0.662–0.934 | .0062 |
| All-cause hospitalization | RR 0.796 | 0.741–0.855 | .0004 |
| Pneumonia | RR 0.586 | 0.475–0.722 | .0004 |
| Sepsis | RR 0.735 | 0.605–0.894 | .004 |
| MACE | RR 0.722 | 0.578–0.901 | .0053 |
| Pulmonary embolism | RR 0.608 | 0.440–0.840 | .004 |
| Diabetic ketoacidosis | RR 1.176 | 0.628–2.204 | NS |
| Hyperosmolar hyperglycemic state | RR 0.558 | 0.268–1.162 | NS |
Study Facts Table
| Field | Detail |
|---|---|
| Authors | Mahadevan A, Vosooghi A, Arora JS, Sunil Kumar R, Singh G, Tsai KK, Quandt Z |
| Journal | Journal of Clinical Endocrinology & Metabolism |
| Year | 2026 (advance access January 2, 2026) |
| DOI | 10.1210/clinem/dgaf703 |
| Design | Retrospective propensity-matched cohort; TriNetX global EHR database |
| Sample size (pre-match) | GLP-1RA: 3,747; metformin: 52,061; new-start GLP-1RA: 1,670; new-start insulin: 13,910 |
| Sample size (post-match) | 3,551 per arm (overall); 1,620 per arm (new-start) |
| Population | Adults with T2D (ICD-10 E11) and top-10 causes of cancer-related death; systemic cancer therapy initiated January 2010 or later |
| Intervention | GLP-1RA (any of: liraglutide, dulaglutide, semaglutide, exenatide, tirzepatide) within ±3 months of first systemic cancer therapy |
| Comparator | Metformin monotherapy (overall); insulin (new-start cohort) |
| Primary endpoint | All-cause mortality (Kaplan-Meier, landmarked at 6 months post-systemic therapy) |
| Key results | Overall mortality HR 0.875 (0.778–0.985, P=.0268); new-start HR 0.786 (0.662–0.934, P=.0062); hospitalization RR 0.796 (0.741–0.855, P=.0004) |
| Adverse events | DKA numerically higher with GLP-1RA (RR 1.176; NS); HHS similar (RR 0.558; NS) |
| Funding | National Institute of Diabetes and Digestive and Kidney Diseases (K12DK133995 to Z. Quandt) |
| Conflicts of interest | Tsai KK: institutional research funding (ABM Therapeutics, BMS, Genentech, Oncosec, Pfizer, Replimune); consulting honoraria (BMS, Regeneron). Quandt Z: consulting honoraria (Sanofi). All other authors: none declared. |
What Researchers Actually Did
Mahadevan and colleagues queried TriNetX, a federated global EHR network encompassing more than 120 million patients, to assemble two distinct analytic cohorts. The overall cohort included patients with ICD-10-coded T2D who received any GLP-1RA within 3 months before or after starting systemic cancer therapy, compared against patients receiving metformin in the same window. Metformin users were actively excluded from the GLP-1RA arm to enforce monotherapy comparisons. The new-start cohort isolated patients already established on metformin who initiated either a GLP-1RA or insulin within 3 months of their first systemic cancer therapy. Cancer types spanned the top 10 causes of cancer-related death in men and women, incorporating both solid tumor and hematologic malignancies diagnosed from January 2010 forward.
Prior to survival analysis, cohorts underwent 1:1 propensity score matching on age, sex, race, ethnicity, cancer type, presence of distant metastases, surgery, radiation, systemic therapy type, hyperlipidemia, hypertension, smoking, chronic kidney disease, and obesity. Kaplan-Meier survival analyses were landmarked at 6 months after initiation of systemic therapy to mitigate immortal time bias; all analyses required a minimum 3-month gap between any GLP-1RA or metformin initiation and the start of survival follow-up. HbA1c subgroup analyses used values measured within 3 months of systemic therapy initiation. Multiple comparisons were addressed via the Benjamini-Hochberg procedure.
Key Findings: Primary Outcomes
- All-cause mortality, overall cohort: GLP-1RA monotherapy was associated with a statistically significant reduction in mortality compared to metformin monotherapy (HR 0.875; 95% CI 0.778–0.985; P = .0268). Kaplan-Meier curves were followed from 6 months to 2.5 years after cancer treatment initiation.
- All-cause mortality, new-start cohort: Among patients on metformin who initiated a GLP-1RA at the time of cancer therapy versus those who initiated insulin, mortality was further reduced (HR 0.786; 95% CI 0.662–0.934; P = .0062), reflecting a more pronounced signal when the insulin comparator, rather than metformin, serves as the baseline.
- Post-match cohort balance: After propensity matching, 3,551 patients were compared in each arm of the overall cohort. Mean age was 65.3 years in both arms. The GLP-1RA cohort included a modestly lower proportion of White patients (72.8% vs. 75.0%; P = .0375), the only demographic variable achieving post-match statistical difference.
Key Findings: Secondary Outcomes and Subgroup Analyses
Secondary Outcomes (GLP-1RA vs. Metformin)
- All-cause hospitalization: RR 0.796 (95% CI 0.741–0.855; P = .0004) — a 20% relative reduction.
- Pneumonia: RR 0.586 (95% CI 0.475–0.722; P = .0004) — roughly a 41% relative reduction.
- Sepsis: RR 0.735 (95% CI 0.605–0.894; P = .004).
- Major adverse cardiovascular events (MACE): RR 0.722 (95% CI 0.578–0.901; P = .0053).
- Pulmonary embolism: RR 0.608 (95% CI 0.440–0.840; P = .004).
- Diabetic ketoacidosis: RR 1.176 (95% CI 0.628–2.204) — numerically elevated but not statistically significant.
- Hyperosmolar hyperglycemic state: RR 0.558 (95% CI 0.268–1.162) — not statistically significant.
Subgroup Analyses
- HbA1c-stratified survival: Trends toward improved survival with GLP-1RA were observed across optimal (HbA1c 6.5–7%; HR 0.830; 95% CI 0.675–1.020), moderate (7–9%; HR 0.821; 95% CI 0.665–1.014), and suboptimal (>9%; HR 0.762; 95% CI 0.539–1.077) glycemic control, but none met statistical significance after Benjamini-Hochberg correction (all P = .128).
- Obesity subgroup: Obese patients showed a trend toward improved survival (HR 0.877; 95% CI 0.759–1.013; P = .156) that did not reach significance; non-obese patients demonstrated no survival difference (HR 1.036; 95% CI 0.838–1.279; P = .746).
- The authors attribute the failure of these subanalyses to reach significance primarily to reduced power, as subgroup samples ranged from 11% to 28% of the primary cohort size.
Adverse Events and Safety Profile
Within the secondary outcomes examined, diabetic ketoacidosis occurred numerically more often in GLP-1RA users (RR 1.176; 95% CI 0.628–2.204), though the wide confidence interval and lack of statistical significance preclude firm conclusions. No prior literature has explicitly examined the GLP-1RA-DKA relationship in patients with active cancer, and the authors acknowledge this gap. Hyperosmolar hyperglycemic state rates were similar between groups (RR 0.558; 95% CI 0.268–1.162; NS). The database methodology precludes granular adverse event capture beyond these ICD-10-coded outcomes; patient-reported events, infusion reactions, gastrointestinal toxicity from GLP-1RAs, or events not triggering a coding encounter are undetectable in this dataset.
Statistical Approach and Rigor
The study employed 1:1 propensity score matching on 14 prespecified covariates, which is a defensible strategy in a large observational dataset. The use of 6-month landmark analysis is methodologically important: it limits immortal time bias that would otherwise artificially inflate benefits in the GLP-1RA arm, since patients must survive long enough to be included. The Benjamini-Hochberg false discovery rate procedure was applied for multiple comparisons across secondary and subgroup outcomes. However, several statistical realities warrant scrutiny. The primary cohort is substantially imbalanced before matching (3,747 GLP-1RA users vs. 52,061 metformin users), meaning a large fraction of the metformin pool was discarded. The survival follow-up
Read This Paper Through Nine Different Lenses
The same evidence can produce very different conclusions depending on the question being asked. Explore this study through multiple physician-guided interpretive frameworks.
Overview
This study demonstrates that GLP-1 receptor agonists (GLP-1RAs) are associated with reduced all-cause mortality and hospitalization rates in cancer patients with type 2 diabetes compared to metformin. The findings suggest potential benefits of GLP-1RAs in oncology settings, but further prospective studies are needed for confirmation.
- GLP-1RA monotherapy reduces all-cause mortality by 12.5%.
- Lower rates of hospitalization and specific adverse events were observed with GLP-1RA use.
- Subgroup analyses did not reach statistical significance, likely due to reduced power.
Patient Takeaway
Cancer patients with type 2 diabetes may benefit from GLP-1 receptor agonists (GLP-1RAs) as they are associated with reduced mortality and hospitalization rates. However, individual responses can vary, so it is important to discuss treatment options with a healthcare provider.
- GLP-1RA use is linked to improved survival outcomes.
- Lower risks of sepsis, pneumonia, and pulmonary embolism were observed.
- Consultation with a healthcare provider is crucial for personalized treatment decisions.
Clinician’s POV
Clinicians can consider GLP-1 receptor agonists (GLP-1RAs) for cancer patients with type 2 diabetes based on the study findings, which show reduced mortality and hospitalization rates. However, further research is needed to confirm these benefits.
- GLP-1RA monotherapy reduces all-cause mortality by 12.5%.
- Lower risks of sepsis, pneumonia, pulmonary embolism, and MACE were observed.
- Prospective studies are necessary for confirmation and exploration of mechanisms.
A Skeptical Read
While the study suggests that GLP-1 receptor agonists (GLP-1RAs) may reduce mortality and hospitalization in cancer patients with type 2 diabetes, critical analysis is warranted. The observational nature of the study and lack of subgroup significance highlight areas for further investigation.
- Observational design limits causal inference.
- Subgroup analyses did not reach statistical significance.
- Further prospective studies are needed to confirm findings.
Study Critic
Critics may point to the observational design and lack of subgroup significance as limitations. However, the study’s methodological rigor, including propensity score matching and landmark analysis, strengthens its findings.
- Observational design precludes causal inference.
- Subgroup analyses lacked statistical power.
- Methodological rigor supports key findings.
Compared to Past Research
Previous preclinical studies suggested that GLP-1 receptor agonists (GLP-1RAs) may inhibit tumor progression and improve glycemic control. This study provides clinical evidence supporting these findings in cancer patients with type 2 diabetes.
- Preclinical studies indicated potential anti-cancer effects of GLP-1RAs.
- Improved glycemic control is a known benefit of GLP-1RA use.
- Clinical evidence now supports preclinical findings in specific patient populations.
Practical Considerations
Practically, clinicians can consider GLP-1 receptor agonists (GLP-1RAs) for cancer patients with type 2 diabetes based on the study findings. However, individual patient factors and treatment preferences should guide clinical decisions.
- GLP-1RA use is associated with improved survival outcomes.
- Lower risks of hospitalization and specific adverse events were observed.
- Individualized care is essential for optimal patient outcomes.
Future Directions
Future research should focus on confirming the study’s findings through prospective, well-controlled trials. Additionally, exploring the mechanisms by which GLP-1RAs improve outcomes in cancer patients with type 2 diabetes is crucial.
- Prospective studies are needed to confirm benefits.
- Mechanistic studies can elucidate how GLP-1RAs impact cancer progression.
- Further research will guide clinical practice and patient care.
Misreadings & Bad-Faith Takes
Common misinterpretations of the study include assuming causation from correlation and overgeneralizing findings to all cancer patients. It is important to clarify that the study’s benefits are specific to cancer patients with type 2 diabetes.
- Observational design does not establish causation.
- Findings are specific to cancer patients with type 2 diabetes.
- Overgeneralization can lead to misinterpretation of results.
Have thoughts on this? Share it:
What are GLP-1 receptor agonists?
GLP-1 receptor agonists (GLP-1RAs) are medications that mimic the effects of glucagon-like peptide-1, a hormone that helps regulate blood sugar levels and may have anti-cancer properties.
How do GLP-1RAs affect cancer patients with diabetes?
GLP-1RAs are associated with reduced all-cause mortality, lower hospitalization rates, and decreased risks of sepsis, pneumonia, pulmonary embolism, and major adverse cardiovascular events in cancer patients with type 2 diabetes.
What was the study design?
The study used a retrospective propensity-matched cohort design from TriNetX, a global electronic health record database, to compare outcomes between GLP-1RA and metformin users.
What were the key findings?
GLP-1RA monotherapy was associated with a 12.5% reduction in all-cause mortality compared to metformin, with additional benefits seen in hospitalization and specific adverse events.
How does this study compare GLP-1RAs to insulin?
In a subanalysis of patients newly started on GLP-1RA or insulin, GLP-1RA was associated with even greater reductions in mortality.
What are the limitations of this study?
The study is observational and lacks a randomized controlled trial design. Additionally, subgroup analyses did not reach statistical significance due to reduced power.
Are there any adverse effects mentioned in the study?
Diabetic ketoacidosis occurred more frequently in GLP-1RA users, though it was not statistically significant. Hyperosmolar hyperglycemic state rates were similar between groups.
What is the significance of this research?
This study suggests that GLP-1RAs may offer survival benefits for cancer patients with type 2 diabetes, warranting further investigation in prospective studies.
Who should consider using GLP-1RAs based on this study?
Cancer patients with type 2 diabetes might benefit from discussing the potential use of GLP-1RAs with their healthcare providers, especially if they are currently taking metformin.
What future research is needed?
Prospective, well-controlled studies are necessary to confirm these findings and explore the mechanisms by which GLP-1RAs may improve outcomes in cancer patients with diabetes.
